



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION

Riluzole-¹³C,¹⁵N₂
Item No. 25361



CAS Registry No.: 1215552-03-6
Formal Name: 6-(trifluoromethoxy)benzo[d]thiazol-2-¹³C-3-¹⁵N-2-amine-¹⁵N
MF: C₇[¹³C]H₅F₃[¹⁵N]₂OS
FW: 237.2
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Riluzole-¹³C,¹⁵N₂ is supplied as a solid. A stock solution may be made by dissolving the riluzole-¹³C,¹⁵N₂ in the solvent of choice. Riluzole-¹³C,¹⁵N₂ is soluble in organic solvents such as methanol and chloroform, which should be purged with an inert gas.

Description

Riluzole-¹³C,¹⁵N₂ is intended for use as an internal standard for the quantification of riluzole (Item No. 14577) by GC- or LC-MS. Riluzole is a benzothiazole derivative with anti-excitotoxic effects that acts by blocking the presynaptic release of glutamate, indirectly antagonizing glutamate receptors, and inactivating neuronal voltage-gated Na⁺ channels (ED₅₀ = 2.3 μM).¹ Riluzole suppresses glutamate-induced seizures in rats at an ED₅₀ value of 3.2 mg/kg and displays neuroprotective effects in hypoxic animals at an ED₅₀ value of 4 mg/kg. Formulations containing riluzole have been explored as therapeutics for slowing disease progression of amyotrophic lateral sclerosis.

Reference

1. Cheah, B.C., Vucic, S., Krishnan, A.V., *et al.* Riluzole, neuroprotection and amyotrophic lateral sclerosis. *Curr. Med. Chem.* **17**(18), 1942-1959 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/04/2018

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM